Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Non-Current Deffered Revenue (2017 - 2025)

Historic Non-Current Deffered Revenue for Arcus Biosciences (RCUS) over the last 9 years, with Q3 2025 value amounting to $53.0 million.

  • Arcus Biosciences' Non-Current Deffered Revenue fell 8166.09% to $53.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $53.0 million, marking a year-over-year decrease of 8166.09%. This contributed to the annual value of $234.0 million for FY2024, which is 2377.85% down from last year.
  • As of Q3 2025, Arcus Biosciences' Non-Current Deffered Revenue stood at $53.0 million, which was down 8166.09% from $60.0 million recorded in Q2 2025.
  • Over the past 5 years, Arcus Biosciences' Non-Current Deffered Revenue peaked at $462.0 million during Q4 2021, and registered a low of $53.0 million during Q3 2025.
  • Over the past 5 years, Arcus Biosciences' median Non-Current Deffered Revenue value was $289.0 million (recorded in 2024), while the average stood at $263.3 million.
  • In the last 5 years, Arcus Biosciences' Non-Current Deffered Revenue skyrocketed by 111929.12% in 2021 and then tumbled by 8166.09% in 2025.
  • Arcus Biosciences' Non-Current Deffered Revenue (Quarter) stood at $462.0 million in 2021, then dropped by 23.16% to $355.0 million in 2022, then fell by 13.52% to $307.0 million in 2023, then fell by 23.78% to $234.0 million in 2024, then plummeted by 77.35% to $53.0 million in 2025.
  • Its Non-Current Deffered Revenue stands at $53.0 million for Q3 2025, versus $60.0 million for Q2 2025 and $219.0 million for Q1 2025.